Prostate cancer IHC panel

Prostate IHC assay
Prostate cancer diagnostic solutions
Prostate cancer is a major public health concern. Globally, prostate cancer is the fourth most common cancer (all genders) and the second most common cancer in men.1,2 In the United States, approximately one man in nine will be diagnosed with prostate cancer in his lifetime.3 Approximately 70% of prostate cancer cases are low risk, yet up to 90% are treated aggressively.4
 

We offer a wide menu of immunohistochemistry (IHC) assays. Our portfolio of products delivers the high sensitivity and specificity you need.

Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. We have a robust assay development program focusing on immunohistochemical staining, clinical reagents, cancer diagnostic assays and much more.

Featured assays

immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
VENTANA Basal Cell Cocktail (34ßE12+p63)

VENTANA Basal Cell Cocktail (34βE12+p63) is an antibody cocktail of p63 (4A4) and keratin (34βE12). It may be used to aid in the differentiation of benign lesions with basal cells from malignant prostate lesions lacking basal cells. Identification of basal cells has been an immunohistochemical cornerstone for decades in diagnosis of prostate adenocarcinoma.5,6

Immunohistochemical staining of p504s (SP116) Rabbit Monoclonal Primary Antibody
p504s (SP116) Rabbit Monoclonal Primary Antibody

p504s (SP116) Rabbit Monoclonal Primary Antibody is directed against the p504s enzyme (also known as alpha-Methylacyl Coenzyme A racemase or AMACR). p504s is found to be overexpressed in human prostatic carcinoma, and exhibits a granular, cytoplasmic staining pattern in malignant glands and cells.7

Publications demonstrate the utility of p504s as an aid to the pathologist in recognizing small foci prostatic carcinoma when used to complement an absence of basal cell staining.8 This can be achieved in a dual stain with the Basal Cell Cocktail (34βE12 + p63) to optimize the use of limited available tissue on small focal cancer biopsies.9

ihc detection: NKX3.1 (EP356) Rabbit Monoclonal Primary Antibody
NKX3.1 (EP356) Rabbit Monoclonal Primary Antibody

NKX3.1 (EP356) Rabbit Monoclonal Primary Antibody is a sensitive and specific antibody for the detection of NKX3.1 protein. Publications demonstrate that the reliable detection of NKX3.1 may have utility in a number of clinical applications in prostatic carcinoma and breast carcinomas.10

  • Prostatic carcinoma: There is a high frequency of NKX3.1 expression in prostatic adenocarcinoma with greater than 98% sensitivity and specificity.11,12
  • Gurel et al., demonstrated that nearly all cases of metastatic prostate adenocarcinoma were stained by NKX3.1.12
  • Gurel and Chuang showed that nearly all cases of urothelial carcinoma were negative for NKX3.1.12,13
  • NKX3.1-positive prostate carcinoma cells exhibit nuclear staining.12
Clinical reagents and assays include the p63 (4A4) Mouse Monoclonal Primary Antibody
VENTANA anti-p63 (4A4) Mouse Monoclonal Primary Antibody

The VENTANA anti-p63 (4A4) antibody is directed against the p63 molecule, which is highly expressed in the nuclei of human prostatic basal cells and urothelial tissues. This powerful tool can aid the pathologist in the differential diagnosis of prostate cancer in conjunction with morphological findings. Delivering consistently strong nuclear staining, this antibody may be used to aid in the differentiation of benign and malignant prostatic lesions.14,15

Clinical reagents and assays include the p63 (4A4) Mouse Monoclonal Primary Antibody
anti-ERG (EPR3864) Rabbit Monoclonal Primary Antibody

The ERG (EPR3864) Rabbit Monoclonal Primary Antibody is capable of detecting: Truncated ERG resulting from TMPRSS2:ERG (or other ERG gene fusions) and wildtype ERG (most notably expressed in vessel endothelium).16 This antibody exhibits a nuclear staining pattern and may be used to aid in the identification of prostate adenocarcinomas through the detection of truncated ERG.17,18 TMPRSS2-ERG gene fusions occur in 50% of prostate cancers and result in the overexpression of a chimeric fusion transcript that encodes a truncated ERG product. Anti-ERG (EPR3864) Rabbit Monoclonal Primary Antibody may facilitate functional studies of ERG gene fusions and subtyping of prostate cancer.19

Take an in-depth look at our full prostate cancer IHC assay panel.

Search our product catalogs and documentation library in eLabDoc.

Roche Prostate IHC panel in eLabDoc

  1. WHO Global Cancer Observatory Website https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf accessed December 16, 2020
  2. WHO Global Cancer Observatory Website https://gco.iarc.fr/today/online-analysis-pie? accessed on December 16, 2020
  3. American Cancer Society key statistics about prostate cancer? American Cancer Society Website https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html accessed November 18, 2020
  4. Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Lee, P. A., & McMahon, P. M. (2013). Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Annals of internal medicine, 158(12), 853–860. https://doi.org/10.7326/0003-4819-158-12-201306180-00002
  5. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res1985; 45(8):3663-7.
  6. Epstein, Jonathan I. MD*; Egevad, Lars MD, PhD†; Humphrey, Peter A. MD, PhD‡; Montironi, Rodolfo MD§ Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate, The American Journal of Surgical Pathology: August 2014 - Volume 38 - Issue 8 - p e6-e19 
  7. Jiang J et al. Using an AMACR (P504S/34βE12/p63 Cocktail for the Detection of Small Focal Prostate Carcinoma in Needle Biopsy Specimens. Am J Clin Pathol. 2005; 123:231-236.
  8. Epstein, J I. Diagnosis of limited adenocarcinoma of the prostate. Histopathology. 2012; 60:28-40.
  9. Ng, V W et al. Is Triple Immunostaining With 34βE12, p63, and Racemase in Prostate Cancer Advantageous? A Tissue Microarray Study. Am J Clin Pathol. 2007; 127:248-253. 
  10. Asch-Kendrick R, et al. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas. J Clin Pathol. 2014; 67:768-71. 
  11. NKX3.1 (EP356) Package Insert
  12. Gurel B, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010; 34:1097-1105.
  13. Chuang A, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007; 31:1246-55.
  14. Weinstein MH, et al. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 2002; 15:1302-1308.
  15. Parsons et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001; 58:619-24.
  16. Tomlins, S. A., Palanisamy, N., Siddiqui, J., Chinnaiyan, A. M., & Kunju, L. P. (2012). Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Archives of pathology & laboratory medicine, 136(8), 935–946. https://doi.org/10.5858/arpa.2011-0424-OA
  17. anti-ERG (EPR3864) Rabbit Monoclonal Primary Antibody Package Insert
  18. Shah R B, et al. The diagnostic use of ERG in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoAracemase markers. Human pathology. 2013; 44(5): 786 -794.
  19. Park, K et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7): 590.
Prostate cancer diagnostic solutions

Prostate cancer is a major public health concern. Prostate cancer is the second most common cancer in men.1 Approximately one man in seven will be diagnosed with prostate cancer in his lifetime.2 Approximately 70% of prostate cancer cases are low risk, yet up to 90% are treated aggressively.3

We offer a wide menu of immunohistochemistry (IHC) assays. Our portfolio of products delivers the high sensitivity and specificity you need.

Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. We have a robust assay development program focusing on immunohistochemical staining, clinical reagents, cancer diagnostic assays and much more.